First Tracks Biotherapeutics reported that ANB033 protected the gut and kept symptoms from worsening during a 14-day gluten challenge. The Cohort 1 Phase 1b result is early and does not show lasting benefit.
The findings give First Tracks Biotherapeutics an early sign that ANB033 may help people with celiac disease handle gluten exposure. This supports the company's treatment effort. The result comes from Cohort 1 of an early trial. The 14-day test does not show whether the protection lasts or works in daily life. The initial patient benefit is encouraging, with important questions still open.
C3.ai received an analyst upgrade and a higher target price, a favorable outside view. The report gives no new company results.
Reports say GTCR and Elliott are close to a deal to acquire CCC Intelligent Solutions, raising the chance of a sale. No signed deal or terms are reported, so the benefit is not certain.
Liquidia Corporation is listed among stocks that rose, but the story gives no company news explaining why. It does not change the outlook for the company.
Borr Drilling shares are listed as having risen, but the story gives no company news explaining why. It does not change the outlook for the company.
Allot shares are listed as having risen, but the story gives no company news explaining why. It does not change the outlook for the company.
Follow First Tracks Biotherapeutics, Inc. (TRAX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TRAX